Intermediate for Ibrutinib. Ibrutinib (trade name: Imbruvica) is a small Bruton's tyrosine kinase (BTK) inhibitor. Ibrutinib is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia, a form of non-Hodgkin's lymphoma. Ibrutinib has been approved by the U.S Food and Drug Administration on November 19, 2013.


Product Name:                  4-Amino-3-iodo-1H-pyrazolo[3,4-D]pyridine

Synonyms:                         N/A

CAS Number:                     151266-23-8

Molecular Weight:            261.0246

Molecular Formula:          C5H4IN5

Purity (HPLC):                     ≥95%

Shipping Conditions:         Room temperature.

Storage Conditions:           Refrigerated.

Regulatory Statement:      For Research Use Only.

SMILES:                               Nc1ncnc2c1c(I)n[nH]2

  • $208.00
  • Ex Tax: $208.00

Available Options